Krilogy Financial LLC Invests $1.47 Million in Becton, Dickinson and Company $BDX

Krilogy Financial LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 8,332 shares of the medical instruments supplier’s stock, valued at approximately $1,470,000.

Other large investors have also bought and sold shares of the company. ABC Arbitrage SA bought a new stake in Becton, Dickinson and Company in the third quarter valued at $1,159,000. Stratos Wealth Partners LTD. grew its stake in shares of Becton, Dickinson and Company by 5.2% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 16,881 shares of the medical instruments supplier’s stock valued at $3,160,000 after buying an additional 841 shares during the period. Providence Capital Advisors LLC increased its position in Becton, Dickinson and Company by 3.3% in the 3rd quarter. Providence Capital Advisors LLC now owns 35,043 shares of the medical instruments supplier’s stock valued at $6,559,000 after buying an additional 1,124 shares in the last quarter. Midwest Trust Co raised its stake in Becton, Dickinson and Company by 14.0% during the 3rd quarter. Midwest Trust Co now owns 52,870 shares of the medical instruments supplier’s stock worth $9,896,000 after buying an additional 6,492 shares during the period. Finally, Wealthfront Advisers LLC boosted its holdings in Becton, Dickinson and Company by 35.4% in the third quarter. Wealthfront Advisers LLC now owns 18,043 shares of the medical instruments supplier’s stock worth $3,377,000 after acquiring an additional 4,713 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Jefferies upgraded BDX to a Buy, providing direct bullish pressure that can support the stock as investors reframe valuation vs. the new pure‑play MedTech focus. Becton Dickinson (BDX) Gets a Buy from Jefferies
• Positive Sentiment: BD completed its Biosciences & Diagnostics spin‑off and merged that business with Waters, locking in roughly $4B in proceeds and accelerating a pivot to a pure‑play MedTech company — a structural catalyst for longer‑term re‑rating. BD Merges Biosciences & Diagnostics Business With Waters
• Positive Sentiment: Q4 results and commentary showed a sales surprise and management highlighted portfolio reshaping and product investments that offset tariff headwinds — supportive for medium‑term margin recovery expectations. BDX Q4 Deep Dive: Portfolio Reshaping and Product Investments Offset Tariff Headwinds
• Positive Sentiment: High‑profile bullish commentary (e.g., Jim Cramer) is adding retail investor interest and narrative support for the “new company” story after the restructuring. Jim Cramer on Becton, Dickinson: “I kind of really like the new company”
• Neutral Sentiment: TD Cowen nudged its price target to $189 from $183 but kept a Hold rating — a modest signal that sentiment is mixed, offering limited near‑term directional impact. TD Cowen Adjusts Becton, Dickinson and Company PT to $189 from $183; Maintains Hold Rating
• Negative Sentiment: Multiple large banks issued pessimistic forecasts or analyst downgrades (JPMorgan, Wells Fargo), increasing selling pressure and contributing to the morning gap down. JPMorgan Chase & Co. Issues Pessimistic Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price
• Negative Sentiment: Wells Fargo’s pessimistic outlook added to the analyst sell‑side momentum and volatility pressure. Wells Fargo & Company Issues Pessimistic Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price
• Negative Sentiment: Citigroup trimmed its price target (publication notes a lower target), and at least one downgrade produced an early‑session gap down — clear near‑term negatives despite the firm’s longer‑term cash/reshaping positives. Citigroup Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $232.00
• Negative Sentiment: Coverage notes that BDX shares gapped down on an analyst downgrade, signalling immediate selling pressure and higher intraday volume as investors digest mixed signals. Becton, Dickinson and Company (NYSE:BDX) Shares Gap Down on Analyst Downgrade

Becton, Dickinson and Company Price Performance

BDX opened at $177.93 on Friday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $185.02. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.64. The company has a market capitalization of $50.66 billion, a price-to-earnings ratio of 29.03, a P/E/G ratio of 2.38 and a beta of 0.25. The firm’s fifty day moving average price is $199.18 and its two-hundred day moving average price is $192.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the prior year, the company posted $3.43 earnings per share. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is presently 68.52%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a share buyback program on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Wells Fargo & Company decreased their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a report on Tuesday. Jefferies Financial Group reduced their price target on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Tuesday. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Barclays initiated coverage on shares of Becton, Dickinson and Company in a report on Tuesday. They set an “overweight” rating and a $202.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Five investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $195.46.

Insider Activity

In related news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 2,463 shares of company stock valued at $501,530 over the last three months. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.